Antibacterial Drug Development: A New Approach Is Needed for the Field to Survive and Thrive

Autor: M. Courtney Safir, Sujata M. Bhavnani, Christine M. Slover, Paul G. Ambrose, Christopher M. Rubino

Publikováno v: Antibiotics, Vol 9, Iss 7, p 412 (2020)

It is often said that the marketplace for new antibiotics is broken. This notion is supported by the observation that many recently-approved antibiotics to treat drug-resistant bacteria have failed commercially in a spectacular fashion. Today, compan

Externí odkaz: https://doaj.org/article/bbd1d0f52f5c412a87b761932369bf2f

Pharmacokinetic-Pharmacodynamic Target Attainment Analyses Evaluating Omadacycline Dosing Regimens for the Treatment of Patients with Community-Acquired Bacterial Pneumonia Arising from Streptococcus pneumoniae and Haemophilus influenzae

Autor: Sujata M. Bhavnani, Jeffrey P. Hammel, Elizabeth A. Lakota, Michael Trang, Justin C. Bader, Catharine C. Bulik, Brian D. VanScoy, Christopher M. Rubino, Michael D. Huband, Lawrence Friedrich, Judith N. Steenbergen, Paul G. Ambrose

Publikováno v: Antimicrobial Agents and Chemotherapy. 67

Omadacycline, a novel aminomethylcycline with in vitro activity against Gram-positive and -negative organisms, including Streptococcus pneumoniae and Haemophilus influenzae , is approved in the United States to treat patients with community-acquired

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::f512cb865e5b1e50a1aff17b6dce35ce
https://doi.org/10.1128/aac.02213-21

592. Impact of Elevated MIC Values on Echinocandin Pharmacokinetic-Pharmacodynamic (PK-PD) Candida glabrata Target Attainment (TA)

Autor: Christopher M Rubino, Shawn Flanagan, Jeffrey B Locke, Sujata M Bhavnani

Publikováno v: Open Forum Infectious Diseases. 9

Background Given the increasing prevalence of non-albicans Candida species, including C. glabrata and C. auris, which have higher predisposition to develop antifungal resistance (e.g., fks mutations conferring reduced susceptibility to echinocandins)

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::26ea862b210f436fd207863ebf479d72
https://doi.org/10.1093/ofid/ofac492.644

LB2306. Population Pharmacokinetic (PPK), Pharmacokinetic/Pharmacodynamic attainment (PTA), and Clinical Pharmacokinetic/Pharmacodynamic (PK/PD) Analyses for Sulbactam-Durlobactam (SUL-DUR) to Support Dose Selection for the Treatment of Acinetobacter baumannii-calcoaceticus Complex (ABC) Infections

Autor: Sujata M Bhavnani, Christopher M Rubino, Jeffrey P Hammel, Anthony P Cammarata, Kajal Larson, Kathryn Liolios, Sarah McLeod, Alita Miller, Paul G Ambrose, Ruben Tommasi, John O'Donnell

Publikováno v: Open Forum Infectious Diseases. 9

Background SUL-DUR is a β-lactam/β-lactamase inhibitor combination in development for the treatment of ABC infections, which are often severe and associated with substantial mortality. PPK, PTA, and clinical PK/PD analyses were conducted using all

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::f4d2a3d650c63780862254dacfb13767
https://doi.org/10.1093/ofid/ofac492.1896

Population Pharmacokinetic Evaluation of Amikacin Liposome Inhalation Suspension in Patients with Treatment-Refractory Nontuberculous Mycobacterial Lung Disease

Autor: Dayton W. Yuen, Nikolas J. Onufrak, Christopher M. Rubino, Jakko van Ingen, David E. Griffith, Kevin C. Mange, Kevin L. Winthrop, Sujata M. Bhavnani

Publikováno v: European Journal of Drug Metabolism and Pharmacokinetics
European Journal of Drug Metabolism and Pharmacokinetics, 46, 277-287
European Journal of Drug Metabolism and Pharmacokinetics, 46, 2, pp. 277-287

Background and Objectives Use of parenteral amikacin to treat refractory nontuberculous mycobacterial (NTM) lung disease is limited by systemic toxicity. A population pharmacokinetic model was developed using data pooled from two randomized trials to

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8d16980a61a948d84c59c434de74690a
https://doi.org/10.1007/s13318-020-00669-7